other material
confidence high
sentiment positive
materiality 0.60
Personalis expands Tempus partnership to colorectal cancer MRD; term to 2029
Personalis, Inc.
- Tempus authorized to market NeXT Personal MRD test for colorectal cancer, fourth indication.
- Agreement term extended to November 25, 2029.
- Exclusivity period extended to December 31, 2028 for both parties on tumor-informed MRD in these indications.
- Standstill restrictions for Tempus modified to expire June 4, 2027 or end of exclusivity.